<DOC>
	<DOCNO>NCT01085591</DOCNO>
	<brief_summary>This randomize , double-blind , single-placebo , active-controlled , dose range parallel group design 3 arm . Two dose regimen CB-183,315 dose twice daily compare active comparator oral vancomycin ( 125 milligram ( mg ) four time daily ) . Participants diarrhea risk Clostridium difficile infection ( CDI ) [ example , receive prior concomitant antibiotic ( ) ] identify tested C. difficile toxin stool use enzyme immunoassay ( EIA ) , polymerase chain reaction ( PCR ) per usual standard care . Eligible participant consent , undergo baseline evaluation , randomize blind fashion one 3 treatment arm . Participants randomize receive either 125 mg CB-183,315 twice daily alternate placebo tablet twice daily , 250 mg CB-183,315 twice daily alternate placebo tablet twice daily 125 mg oral vancomycin four time dailyover period 10 day 1:1:1 fashion .</brief_summary>
	<brief_title>Study CB-183,315 Participants With Clostridium Difficile Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>To eligible enrollment , participant must meet following criterion prior study related procedure : Informed Consent obtain sign Age ≥ 18 year If female , participant nonlactating , either : Not childbearing potential , defined postmenopausal least 1 year surgically sterile due bilateral tubal ligation , bilateral oophorectomy , hysterectomy Of childbearing potential practice barrier method birth control along one follow method : oral parenteral contraceptive 3 month prior study drug administration , vasectomized partner , abstinence sexual intercourse Established nonsevere severe CDI ( Data Monitoring Committee [ DMC ] review ) positive stool test toxin A and/or B within 72 hour prior first dose study drug . A participant enrol s/he meet follow criterion : Female pregnant lactate Toxic megacolon and/or know small bowel ileus Received treatment intravenous ( IV ) immune globulin within 30 day prior first dose study drug Antibacterial therapy specific current CDI may effective CDI even give different indication : Received 24 hour oral vancomycin current episode CDI prior first dose study drug . Received 24 hour oral/intravenous metronidazole OR therapy specific current episode CDI immediately prior first dose study drug unless participant receive least 3 day therapy , consider treatment failure CDI . Received 24 hour oral/intravenous metronidazole indication 3 day prior first dose study drug . Participants 2 episode CDI within 90 day ( , participant enrol 1st recurrence/2nd episode ) Major gastrointestinal ( GI ) surgery ( , significant bowel resection include total colectomy ileostomy ) within 3 month enrollment ( include appendectomy cholecystectomy ) History prior inflammatory bowel disease : ulcerative colitis , Crohn 's disease , microscopic colitis Unable stop loperamide , diphenoxylate , cholestyramine duration study Unable stop opiate treatment , unless stable dose onset diarrhea change dose plan duration study Known positive stool culture enteropathogens , include limited Salmonella , Shigella Campylobacter Known stool study positive ova and/or parasite Known intolerance hypersensitivity daptomycin and/or vancomycin Poor concurrent medical risk clinically significant comorbid disease opinion Investigator participant enrol Received investigational drug participate experimental procedure within 1 month prior study entry Previously enrol study Received investigational vaccine C. difficile Participants know Hepatitis B Hepatitis C alanine aminotransferase aspartate aminotransferase &gt; 2.5 time upper limit normal ( ULN ) and/or bilirubin &gt; 1.5 time ULN Human immunodeficiency virus positive , unless control ( , triple therapy ) CD4 &gt; 200 cell per millimeter cubed ( cellsmm˄3 ) Anticipated systemic antibacterial therapy nonCDI infection require &gt; 7 day start study therapy Concurrent therapy daptomycin Unable discontinue Saccharomyces similar probiotic Known active IV drug alcohol abuse Concurrent intensive chemotherapy , radiotherapy biologic treatment active malignancy ( may enrol consultation Medical Monitor ) Unable comply protocol requirement Any condition , opinion Investigator , might interfere study objective Life expectancy le 6 week Additional Exclusions Participants Severe CDI In addition criterion list , participant meet definition severe CDI enrol participant meet follow criterion : Age &gt; 80 Hypotension , define sustain systolic blood pressure &lt; 90 millimeter mercury ( mmHg ) , need vasopressor maintain blood pressure Abdominal rebound tenderness examination Acute kidney insufficiency define : oliguria ( &lt; 20 cubic centimeter [ cc ] urine output per hour 4 hour period responsive attempt increase renal perfusion ) nonperfusion ( example , prerenal ) relate azotemia initial creatinine ( Baseline ) &gt; 2.5 milligram per deciliter ( mg/dL ) blood urea nitrogen ( BUN ) &gt; 40 mg/dL prior history chronic kidney disease Unable tolerate oral medication due persistent vomit 2 . White blood cell ( WBC ) count &gt; 30,000/mm˄3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CDI</keyword>
	<keyword>Clostridium difficile Infection</keyword>
	<keyword>Diarrhea</keyword>
</DOC>